Qual é o preço para Clarus Therapeutics Holdings, Inc. (CRXTQ)

O preço para Clarus Therapeutics Holdings, Inc. (CRXTQ) é $0.0014

Qual é a capitalização de mercado para Clarus Therapeutics Holdings, Inc. (CRXTQ)

A capitalização de mercado para Clarus Therapeutics Holdings, Inc. (CRXTQ) é $72.83K

Histórico de Preços de Clarus Therapeutics Holdings, Inc. (CRXTQ)

Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.

Ano	Desempenho
2023	-93.65%
2022	0.00%

Ano

Desempenho

2023

-93.65%

2022

0.00%

Empresa	Preço da ação	Variação 1a%	País
Eli Lilly and Company LLY.US	$1.22K	84.86%	US
Johnson & Johnson JNJ.US	$261.78	50.09%	US
AbbVie Inc. ABBV.US	$250.59	24.38%	US
Roche Holding AG RO.SW	$478.35	47.12%	CH
Merck & Co., Inc. MRK.US	$134.85	63.04%	US

Empresa

Preço da ação

Variação 1a%

País